Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 45, Issue 10, 2017, Pages 1303-1318

  Aksan, A ^a,b   Isik H ^a   Radeke, H H ^b,c   Dignass, A ^b,d   Stein, J ^b,e  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Crohn Colitis Center Rhein Main   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^d AGAPLESION MARKUS KRANKENHAUS   (Germany)

^e Department of Gastroenterology ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; FERRIC CARBOXYMALTOSE; HEMOGLOBIN; IRON; IRON DEXTRAN; IRON ISOMALTOSE; IRON ISOMALTOSIDE; IRON SACCHARATE; UNCLASSIFIED DRUG;

ANAPHYLAXIS; BURNING SENSATION; COMPARATIVE EFFECTIVENESS; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEVER; HEADACHE; HUMAN; HYPERFERRITINEMIA; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; INFLAMMATORY BOWEL DISEASE; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; LUNG EMBOLISM; META ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TASTE DISORDER; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE; UNSPECIFIED SIDE EFFECT; ANEMIA, IRON-DEFICIENCY; COMPLICATION; INFLAMMATORY BOWEL DISEASES; INTRAVENOUS DRUG ADMINISTRATION; NETWORK META-ANALYSIS; QUALITY OF LIFE; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ANEMIA, IRON-DEFICIENCY; DRUG COMPOUNDING; HUMANS; INFLAMMATORY BOWEL DISEASES; IRON; NETWORK META-ANALYSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85016062542     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.14043     Document Type: Review

References (66)

1. Portela F, Lago P, Cotter J, et al. Anaemia in patients with inflammatory bowel disease - a nationwide cross-sectional study. Digestion 2016; 93: 214–20.
2. Goodhand JR, Kamperidis N, Rao A, et al. Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 513–9.
3. Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohn's Colitis 2015; 9: 211–22.
4. Ebinger M, Leidl R, Thomas S, et al. Cost of outpatient care in patients with inflammatory bowel disease in a German University Hospital. J Gastroenterol Hepatol 2004; 19: 192–9.
5. Werlin SL, Grand RJ. Severe colitis in children and adolescents: diagnosis course, and treatment. Gastroenterology 1977; 1: 828–32.
6. Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 2006; 12: 123–30.
7. Nissenson AR, Wade S, Goodnough T, Knight K, Dubois RW. Economic burden of anemia in an insured population. J Manag Care Pharm 2005; 11: 565–74.
8. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 599–610.
9. Avni T, Bieber A, Steinmetz T, Leibovici L, Gafter-Gvili A. Treatment of anemia in inflammatory bowel disease–systematic review and meta-analysis. PLoS ONE 2013; 8: e75540.
10. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther 2006; 24: 1507–23.
11. Nielsen OH, Ainsworth M, Coskun M, Weiss G. Management of iron-deficiency anemia in inflammatory bowel disease: a systematic review. Medicine 2015; 94: e963.
12. Guagnozzi D, Lucendo AJ. Anemia in inflammatory bowel disease: a neglected issue with relevant effects. World J Gastroenterol 2014; 20: 3542–51.
13. Martin J, Radeke HH, Dignass A, Stein J. Current evaluation and management of anemia in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2017; 11: 19–32.
14. Khalil A, Goodhand JR, Wahed M, Yeung J, Ali FR, Rampton DS. Efficacy and tolerability of intravenous iron dextran and oral iron in inflammatory bowel disease: a case-matched study in clinical practice. Eur J Gastro Hepatol 2011; 23: 1029–35.
15. Zimmermann MB, Chassard C, Rohner F, et al. The effects of iron fortification on the gut microbiota in African children: a randomized controlled trial in Cote d'Ivoire. Am J Clin Nutr 2010; 92: 1406–15.
16. Jaeggi T, Kortman GA, Moretti D, et al. Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut 2015; 64: 731–42.
17. Lee T, Clavel T, Smirnov K, et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut 2016; doi: 10.1136/gutjnl-2015-309940.
18. Kortman GA, Raffatellu M, Swinkels DW, Tjalsma H. Nutritional iron turned inside out: intestinal stress from a gut microbial perspective. FEMS Microbiol Rev 2014; 38: 1202–34.
19. Bonovas S, Fiorino G, Allocca M, et al. Intravenous versus oral iron for the treatment of anemia in inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials. Medicine 2016; 95: e2308.
20. Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc 2015; 90: 12–23.
21. Pratt JJ, Khan KS. Non-anaemic iron deficiency - a disease looking for recognition of diagnosis: a systematic review. Eur J Haematol 2016; 96: 618–28.
22. Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011; 141: 846–853e1.
23. Auerbach M, Coyne D, Ballard H. Intravenous iron: from anathema to standard of care. Am J Hematol 2008; 83: 580–8.
24. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004; 15(Suppl 2): S93–8.
25. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336–41.
26. Furukawa TA, Salanti G, Atkinson LZ, et al. Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. BMJ open 2016; 6: e010919.
27. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ (Clinical research ed.) 2005; 331: 897–900.
28. Salanti G, Marinho V, Higgins JP. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol 2009; 62: 857–64.
29. Cipriani A, Higgins JP, Geddes JR, Salanti G. Conceptual and technical challenges in network meta-analysis. Ann Intern Med 2013; 159: 130–7.
30. Greco T, Landoni G, Biondi-Zoccai G, D'Ascenzo F, Zangrillo A. A Bayesian network meta-analysis for binary outcome: how to do it. Stat Methods Med Res 2016; 25: 1757–73.
31. Donegan S, Williamson P, D'Alessandro U, Tudur Smith C. Assessing key assumptions of network meta-analysis: a review of methods. Res Synth Methods 2013; 4: 291–323.
32. Kibret T, Richer D, Beyene J. Bias in identification of the best treatment in a Bayesian network meta-analysis for binary outcome: a simulation study. Clin Epidemiol 2014; 6: 451–60.
33. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods 2012; 3: 80–97.
34. Efthimiou O, Debray TP, van Valkenhoef G, et al. GetReal in network meta-analysis: a review of the methodology. Res Synth Methods 2016; 7: 236–63.
35. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010; 29: 932–44.
36. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed.) 2003; 327: 557–60.
37. Mills EJ, Bansback N, Ghement I, et al. Multiple treatment comparison meta-analyses: a step forward into complexity. Clin Epidemiol 2011; 3: 193–202.
38. Neupane B, Richer D, Bonner AJ, Kibret T, Beyene J. Network meta-analysis using R: a review of currently available automated packages. PLoS ONE 2014; 9: e115065.
39. Wang C, Wang X, Chi C, et al. Lung ventilation strategies for acute respiratory distress syndrome: a systematic review and network meta-analysis. Sci Rep 2016; 6: 22855.
40. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients Resolving discordant meta-analyses. JAMA 1996; 275: 308–14.
41. Mills EJ, Kanters S, Thorlund K, Chaimani A, Veroniki AA, Ioannidis JP. The effects of excluding treatments from network meta-analyses: survey. BMJ (Clinical research ed.) 2013; 347: f5195.
42. Gasche C, Dejaco C, Waldhoer T, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med 1997; 126: 782–7.
43. Han YM, Yoon H, Shin CM, et al. Comparison of the efficacies of parenteral iron sucrose and oral iron sulfate for anemic patients with inflammatory bowel disease in Korea. Gut Liv 2016; 10: 562–8.
44. Garcia-Lopez S, Bocos JM, Gisbert JP, et al. High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life. Blood Transfus 2016; 14: 199–205.
45. Gasche C, Waldhoer T, Feichtenschlager T, et al. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol 2001; 96: 2382–7.
46. Koutroubakis IE, Oustamanolakis P, Karakoidas C, Mantzaris GJ, Kouroumalis EA. Safety and efficacy of total-dose infusion of low molecular weight iron dextran for iron deficiency anemia in patients with inflammatory bowel disease. Dig Dis Sci 2010; 55: 2327–31.
47. Millastre J, García-López S, Bajador E, Chaparro M, Gomollon F, Gisbert JP. Su1238 anemia and inflammatory bowel disease: effects of high-dose intravenous iron treatment on hemoglobin, activity index and quality of life. Gastroenterology 2013; 144: S–436.
48. Gisbert JP, Bermejo F, Pajares R, et al. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflamm Bowel Dis 2009; 15: 1485–91.
49. Sobrado CW, Cancado RD, Sobrado LF, Frugis MO, Sobrado MF. Treatment of anemia and improvement of quality of life among patients with Crohn's disease: experience using ferric carboxymaltose. Arq Gastroenterol 2015; 52: 255–9.
50. Beigel F, Lohr B, Laubender RP, et al. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease. Digestion 2012; 85: 47–54.
51. Gasche C, Dejaco C, Reinisch W, et al. Sequential treatment of anemia in ulcerative colitis with intravenous iron and erythropoietin. Digestion 1999; 60: 262–7.
52. Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008; 103: 1182–92.
53. Lindgren S, Wikman O, Befrits R, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 2009; 44: 838–45.
54. Reinisch W, Staun M, Tandon RK, et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol 2013; 108: 1877–88.
55. Schroder O, Mickisch O, Seidler U, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease–a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005; 100: 2503–9.
56. Erichsen K, Ulvik RJ, Nysaeter G, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 2005; 40: 1058–65.
57. Goldberg ND. Iron deficiency anemia in patients with inflammatory bowel disease. Clin Exp Gastroenterol 2013; 6: 61–70.
58. Lee TW, Kolber MR, Fedorak RN, van Zanten SV. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. J Crohn's Colitis 2012; 6: 267–75.
59. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014; 146: 1489–99.
60. Rognoni C, Venturini S, Meregaglia M, Marmifero M, Tarricone R. Efficacy and safety of ferric carboxymaltose and other formulations in iron-deficient patients: a systematic review and network meta-analysis of randomised controlled trials. Clin Drug Invest 2016; 36: 177–94.
61. Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 2014; 99: 1671–6.
62. Goddard AF, James MW, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. Gut 2011; 60: 1309–16.
63. Rimon E, Kagansky N, Kagansky M, et al. Are we giving too much iron? low-dose iron therapy is effective in octogenarians. Am J Med 2005; 118: 1142–7.
64. Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood 2015; 126: 1981–9.
65. Ganzoni AM. New aspects of iron deficiency. Swiss Med Wkly 1970; 100: 691–7.
66. CHMP E. Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product: EMA/CHMP/SWP/620008/2012. London, UK: European Medicines Agency, 2013. http://www.ema.europa.eu/ema/doc_index.jsp.